Adamis Pharmaceuticals traded at $0.07 this Tuesday April 9th, increasing $0.02 or 37.72 percent since the previous trading session. Looking back, over the last four weeks, Adamis Pharmaceuticals gained 1.43 percent. Over the last 12 months, its price fell by 99.01 percent. Looking ahead, we forecast Adamis Pharmaceuticals to be priced at 0.07 by the end of this quarter and at 0.06 in one year, according to Trading Economics global macro models projections and analysts expectations.
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company. It is focused on developing and commercializing products in therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its product includes, SYMJEP (epinephrine) Injection 0.3 miligram for treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more, and SYMJEPI (epinephrine) Injection 0.15 miligram for the treatment of anaphylaxis for patients weighing 33-65 pounds. Its other product candidates includes ZIMHI, a high dose 5 miligram naloxone injection, based on the approved Symject injection device for the treatment of opioid overdose, and APC-400 (tempol) for the treatment of respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19, APC-1000 a hydrofluoroalkane (HFA) inhalable oral steroid for the treatment of asthma and COPD APC-4000 Fluticasone, a dry powder inhalation for the treatment of asthma.